Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA4 | P22748 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.40 |
| ▸ | CDC42 | P60953 | 1/20 | 0.40 |
| ▸ | RAC1 | P63000 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14190061 | 1.00 | PTGS2 (0.43) | PTGS2TSHRLMNAMAPTCYP2C9 | |
| SCHEMBL5140597 | 1.00 | PTGS2 (0.43) | PTGS2TSHRLMNAMAPTCYP2C9 | |
| SCHEMBL14598849 | 0.88 | PTGS2 (0.46) | PTGS2TSHRLMNAMAPTCYP2C9 | |
| Naproxen SCHEMBL7573450 | 0.84 | AKR1C3 (0.50) | PTGS2TSHRLMNAMAPTCYP2C9 | |
| Naproxen SCHEMBL7582595 | 0.84 | AKR1C3 (0.50) | PTGS2TSHRLMNAMAPTCYP2C9 | |
| SCHEMBL13143535 | 0.84 | PTGS2 (0.51) | PTGS2TSHRLMNAMAPTCYP2C9 | |
| SCHEMBL13143519 | 0.84 | PTGS2 (0.51) | PTGS2TSHRLMNAMAPTCYP2C9 | |
| SCHEMBL13143482 | 0.84 | PTGS2 (0.51) | PTGS2TSHRLMNAMAPTCYP2C9 | |
| SCHEMBL13143499 | 0.84 | PTGS2 (0.51) | PTGS2TSHRLMNAMAPTCYP2C9 | |
| SCHEMBL13143503 | 0.84 | PTGS2 (0.51) | PTGS2TSHRLMNAMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010458-A1 | Drugs for the arthritis treatment | NICOX S.A. (FR) | 2007-01-11 | — | — | US | claimed |
| EP-1492543-A1 | DRUGS FOR THE ARTHRITIS TREATMENT | Nicox S.A. (FR) | 2005-01-05 | — | — | EP | claimed |
| WO-2003084550-A1 | DRUGS FOR THE ARTHRITIS TREATMENT | NICOX S.A. (FR) | 2003-10-16 | — | — | WO | claimed |
| US-20070010458-A1 | Drugs for the arthritis treatment | NICOX S.A. (FR) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010458-A1 | Drugs for the arthritis treatment | PTGS1, ADORA2B, PTGS2 | PTGS2 3/4885TSHR 2942/4885LMNA 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.